Eli Lilly

LLY · Health Care · Market cap $1.09T

Q1 FY26 Mar 31, 2026 reported Apr 30, 2026

Revenue$19.8B +56% year over year

Gross profit$16.2B

Operating profit$8.9B

Net profit$7.4B 37% margin

Numbers and detail

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	19.8	100%	+56%
Mounjaro	8.7	44%	+125%
Zepbound	4.2	21%	+80%
Other	1.8	9%
Verzenio	1.3	7%	+12%
Jardiance	1.1	6%	+10%
Other Oncology	1	5%	+22%
Trulicity	0.9	5%	−16%
Other Cardiometabolic Health	0.9	5%	−4%
Cost of revenue	−3.6	18%
Gross profit	16.2	82% margin	−1pp
SG&A	−2.9	15%	−5pp
Other	−4.4	22%	+0pp
Operating profit	8.9	45% margin	+16pp
Tax	−1.4
Interest & other costs	−0.1
Net profit	7.4	37%	+16pp

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	19.3	100%	+43%
Product	18.3	95%	+52%
Collaboration and Other	1	5%	−34%
Cost of revenue	−3.4	18%
Gross profit	15.9	83% margin	+0pp
SG&A	−3.1	16%	−2pp
Other	−4.4	23%	+0pp
Operating profit	8.4	43% margin	+5pp
Tax	−1.7
Interest & other costs	−0.1
Net profit	6.6	34%	+2pp

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	17.6	100%	+54%
Mounjaro	6.5	37%	+109%
Zepbound	3.6	20%	+185%
Other	2	11%
Verzenio	1.5	9%	+7%
Other Cardiometabolic Health	1.1	6%	+1%
Trulicity	1.1	6%	−19%
Jardiance	1	6%	+40%
Other Oncology	0.9	5%	+9%
Cost of revenue	−3	17%
Gross profit	14.6	83% margin	+2pp
SG&A	−2.7	16%	−3pp
Other	−4.5	25%	+0pp
Operating profit	7.4	42% margin	+29pp
Tax	−1.7
Interest & other costs	−0.1
Net profit	5.6	32%	+23pp

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	15.6	100%	+38%
Mounjaro	5.2	33%	+68%
Zepbound	3.4	22%	+172%
Other	1.6	10%
Verzenio	1.5	10%	+12%
Trulicity	1.1	7%	−12%
Other Cardiometabolic Health	1	6%	−16%
Other Oncology	0.9	6%	+12%
Taltz	0.8	5%	+3%
Cost of revenue	−2.4	15%
Gross profit	13.1	84% margin	+3pp
SG&A	−2.8	18%	−1pp
Other	−3.5	22%	+0pp
Operating profit	6.9	44% margin	+11pp
Tax	−1.1
Interest & other costs	−0.1
Net profit	5.7	36%	+10pp

Quarter by quarter

Pick a quarter and the diagram above changes. Bars compare revenue across the quarters we hold.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q1 FY26	Mar 31, 2026	Apr 30, 2026	$19.8B	+56%	45%	$7.4B	37%
Q4 FY25	Oct 1 – Dec 31, 2025	Feb 12, 2026	$19.3B	+43%	44%	$6.6B	34%
Q3 FY25	Jul 1 – Sep 30, 2025	Oct 30, 2025	$17.6B	+54%	42%	$5.6B	32%
Q2 FY25	Apr 1 – Jun 30, 2025	Aug 7, 2025	$15.6B	+38%	44%	$5.7B	36%